Updated data from Akeso and Summit Therapeutics’ China-based Harmoni-6 trial for ivonescimab (a PD-1/VEGF bispecific) showed the PFS benefit narrowing with longer follow-up. The updated dataset has raised new scrutiny as investors and clinicians focus on durability of response in later-line solid tumors. The trial’s longer timepoint is being treated as a signal for how quickly the progression gap closes, a key issue for bispecifics where efficacy must compete with established standards and next-line options. Akeso and Summit now face questions on whether trial endpoints and future development decisions will be recalibrated. For sponsors of similar next-generation immunotherapies, the episode underscores how follow-up maturity can change the perceived value of early readouts.